NCT05675410 2026-03-19
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
10 trialsNCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT07310784 2026-03-03
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
NCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04685616 2026-02-18
RADAR
University College, London
Phase 3 Recruiting
NCT03033914 2026-02-17
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting